Alseres CEO notes molecular-imaging candidate is in Phase III studies

06/12/2008 | PharmaLive.com

Alseres Pharmaceuticals' lead molecular-imaging candidate, Altropane, is in two-part Phase III clinical trials to test its diagnostic efficacy in Parkinson's disease patients with tremor, according to the company chairman and CEO's annual letter to stockholders.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA